Search Results - "de Velasco Oria de Rueda, G."

Incidence, prevalence, and treatment patterns in metastatic hormone-sensitive prostate cancer in Spain: ECHOS study by de Velasco Oria de Rueda, G., Plata Bello, A.C., Landeira, M., Mateo, M., Anguita, P., Pranzo, A., Snijder, R., Garnham, A., Hernández, I.

“…The management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has changed in recent years due to the approval of new drugs. The aim of…”
Get full text

129PThe role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: A meta-analysis of randomized clinical trials by Carretero-Gonzalez, A, Martín Sobrino, I, Sáez Sanz, I, Castellano Gauna, D, De Velasco Oria de Rueda, G A

“…Abstract Background Immune checkpoint inhibitors (ICIs) are beneficial in a subset of metastatic renal cell carcinoma (mRCC) patients. However, no biomarker…”
Get full text

858PRisk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents: A meta-analysis of randomized controlled trials by Mariano, R Coutinho, Gomes, L M, Oliveira, C, Galdino, A C, Araújo, J A P, Vargas, D, Maluf, F C, De Velasco Oria de Rueda, G A, Schutz, F A B

“…Abstract Background New hormonal agents (NHA) have been widely used to treat patients with metastatic and non-metastatic CRPC, with abiraterone, enzalutamide…”
Get full text

877PSerum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study by Laorden, N Romero, Mejorada, R Lozano, Jorge, A Hernández, Lainez, N, Casado, E Almagro, Calvo, O Fernández, Hernando, S, Freire, A Fernández, Billalabeitia, E Gonzalez, Chirivella, I, Domínguez, R García, Herranz, U Anido, Mazon, F J Vazquez, Ros, S, Montesa, A, De Velasco Oria de Rueda, G A, Barrera, R Morales, Lorente, D, Castro, E, Hidalgo, D Olmos

“…Abstract Background Ra223 is a life-prolonging alpha-emitter bone targeted therapy for mCRPC patients with bone metastases. However, evidence on biomarkers…”
Get full text

876PImpact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) by Castro, E, Mejorada, R Lozano, Saez, M, De Giorgi, U F F, Aragón, I, Laorden, N Romero, De Velasco Oria de Rueda, G A, Magraner, L, Pacheco, M I, Puente, J, del Alba, A González, Garcia, P Borrega, Conteduca, V, Guzman, J C Villa, Parra, E Fernandez, Rodriguez-Vida, A, Colmenero, A Medina, Barrera, R Morales, Lorente, D, Hidalgo, D Olmos

“…Abstract Background Ra223 is a bone-seeking a-emitter targeted therapy that induces double-strand DNA breaks (DSBs). The HR pathway is used to accurately…”
Get full text

Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective by Gomez de Liano Lista, A., Necchi, A., Lavaud, P., Carles Galceran, J., Castellano, D., Ravaud, A., Duran, I., van Dijk, N., Giannatempo, P., Loriot, Y., Morales Barrera, R., De Velasco Oria De Rueda, G., Lefort, F., Martínez Bernal, G., Raggi, D., Gross-Goupil, M., Powles, T., van der Heijden, M.

Get full text

864PExternal validation of a prognostic score in first-line metastastic castration-resistant prostate cancer (mCRPC) by Lorente, D, Mejorada, R Lozano, de Rueda, G A De Velasco Oria, Hernandez, A Sanchez, Aliaga, M Rodrigo, Iglesias, Á Sánchez, Campayo, M de Julián, Campos, F Lopez, Laorden, N Romero, Castro, E, Hidalgo, D Olmos

“…Abstract Background Due to improved outcome in mCRPC, most prognostic models may not reflect the current treatment landscape. Recently, Armstrong et al (Ann…”
Get full text

A-308 - A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) by Long, G.V., Gutzmer, R., Haydon, A., Muñoz Couselo, E., Lebbé, C., Carlino, M., Chow, W., Couture, F., Lau, P., Spagnolo, F., Alves Wainstein, A.J., Palmieri, D., Rojas García, C., de Velasco Oria de Rueda, G., Mehmi, I., Patel, D., Shaikh, A., Chowdhury, N.R., Bathena, S., Suryawanshi, S., Rutkowski, P.

Get full text

A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) by Long, G.V., Gutzmer, R., Haydon, A., Muñoz Couselo, E., Lebbé, C., Carlino, M., Chow, W., Couture, F., Lau, P., Spagnolo, F., Alves Wainstein, A.J., Palmieri, D., Rojas García, C., de Velasco Oria de Rueda, G., Mehmi, I., Patel, D., Shaikh, A., Chowdhury, N.R., Bathena, S., Suryawanshi, S., Rutkowski, P.

Get full text